SOUTH SAN FRANCISCO, Calif., August 19, 2025 – Convoke, an AI-native operating system for the biopharmaceutical industry, today announced a $8.6 million seed funding round led by Kleiner Perkins and Dimension Capital, with participation from ACME, Comma Capital, Liquid2, Not Boring Capital, Audacious, Lux Capital, and angel backers including Qasar Younis and Erik Torenberg. The financing aims to accelerate development of Convoke’s platform, which unifies internal and external datasets, codifies decision logic, and autonomously generates high-value deliverables—such as regulatory submissions, manuscripts, and clinical planning documents—significantly reducing the knowledge-work bottlenecks in drug development.
Science Significance
Biopharma remains burdened by “white space” — the vast majority of drug development time wrestled with manual documentation, complex workflows, and fragmented data. Convoke applies large language models and AI agents to gather, synthesize, and interpret scientific, clinical, and regulatory content—reducing months of labor into minutes and enabling teams to iterate and test ideas faster, more precisely, and with consistent rigor.
Regulatory Significance
Regulatory submissions—protocols, investigator brochures, safety documents—often require deep expertise and take months to compile at great cost. Convoke’s platform shortens the timeline significantly; one medical affairs team accelerated a submission by one month using the tool. By increasing the “clock speed” of regulatory readiness, the platform could reshape how agencies and companies prepare approval dossiers, demanding new validation strategies for AI-assisted drafting.
Business Significance
Advertisement
The infusion of $8.6M positions Convoke to scale its engineering and customer base while seeking to fundamentally reshape biopharma workflows. In a high‑stakes industry where delays cost millions per day in unrealized sales, the technology’s potential to reduce time‑to‑market provides a compelling value proposition.convoke.bio+11Axios+11Morningstar+11 Backed by top-tier investors, Convoke aims to unlock a new category of autonomous workflow tools tailored to drug developers of all sizes.
Patients’ Significance
Faster knowledge work translates directly into faster drug development and submission timelines—meaning patients could receive access to novel therapies months or even years earlier. The potential for increased throughput in trial design and regulatory filings may accelerate treatments reaching clinic, address unmet needs faster, and help deliver life‑saving medicines at lower cost.
Policy Significance
As AI becomes embedded in critical drug development workflows, regulators and policymakers must establish standards to ensure accuracy, transparency, and accountability of AI-generated deliverables. Convoke’s approach raises questions around validation, audit trails, authorship, and liability. The shift toward “AI-assisted drug development infrastructure” may trigger new guidance frameworks, public-private partnerships, or regulatory sandbox models to balance innovation with patient safety.
Convoke is spearheading a powerful shift—transitioning drug development from manual, fragmented workflows to AI-driven, scalable, and autonomous operations. The investment marks a critical milestone in reducing barriers between scientific insight and patient impact.
